ASH 2023 | SWOG 1318: dasatinib plus blinatumomab in the treatment of older patients with B-ALL
Harry Erba, MD, PhD, Duke University, Durham, NC, discusses findings from the SWOG 1318 trial (NCT02143414), investigating treatment with dasatinib, a BCR::ABL tyrosine kinase inhibitor (TKi), followed by blinatumomab, a CD19-targeted bispecific antibody, for older patients with B-cell acute lymphoblastic leukemia (B-ALL). This regimen shows encouraging survival outcomes whilst mitigating myelosuppression and reducing the severity of cytokine release syndrome (CRS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Forma: Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Amgen: Research Funding; Macrogenics: Consultancy, Research Funding; Syros: Consultancy; Servier: Consultancy, Honoraria, Research Funding; Kura Oncology: Consultancy, Research Funding; Trillium: Consultancy; ALX Oncology: Research Funding; Gilead: Research Funding; Jazz Pharma: Consultancy, Honoraria, Research Funding; Takeda: Consultancy; Forty-Seven: Research Funding; Ascentage: Research Funding; Pfizer: Consultancy; Incyte: Consultancy, Honoraria; Immunogen: Consultancy, Research Funding; Glycomimetics: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Sunesis Pharmaceuticals: Honoraria; Genentech: Consultancy; BMS: Consultancy, Honoraria, Other: Chair, Myeloid Neoplasms Repository Study; Celgene: Consultancy, Honoraria, Other: Chair, Myeloid Neoplasms Repository Study, Research Funding; Astellas: Consultancy; Agios: Consultancy, Honoraria, Research Funding; Daiichi Sankyo Inc.: Consultancy, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau; PTE: Research Funding; Sumitomo: Research Funding.
